Today: 7 February 2026
Subscribe
Browse Category

Mergers & Acquisitions News 25 October 2025 - 4 November 2025

Denny’s Stock Soars on Buyout Bombshell – $620 M Deal, Q3 Misses & What’s Next

Denny’s Stock Soars on Buyout Bombshell – $620 M Deal, Q3 Misses & What’s Next

Stock Price & Recent Performance Denny’s stock was under pressure for most of 2025 before the buyout news. The share price started the year in the mid-single digits and drifted lower amid uninspiring financial results and sector-wide challenges. In fact, DENN hit a 52-week low of $2.85 earlier in the yearmarketbeat.com, reflecting investors’ pessimism about growth prospects. By late October, the stock was trading around the $4 mark, not far from where it stood five years ago, and well off the 52-week high of $7.73marketbeat.com reached in late 2024. In the week heading into earnings, DENN even dipped below $4
4 November 2025
··
Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Stock Price and Intraday Performance (Nov 3, 2025) Kenvue’s stock soared on the buyout news, delivering a sharp one-day gain. As of midday Nov. 3, KVUE traded around $17–$18, up roughly 18–20% intraday Reuters. Prior to the announcement, the stock had closed at $14.37 on Oct. 31 Stockanalysis, near its 52-week low of ~$14.02 Reuters Reuters. The takeover premium (deal valued at ~$21.01 per share) immediately boosted KVUE, though the share price remained a bit below the offer value – typical in cash/stock mergers as arbitragers factor in execution timing and Kimberly-Clark’s own stock movement (KMB shares fell ~12.5% on
3 November 2025
····
Merger Showdown: Union Slams Crédit Agricole–Banco BPM Deal Over Job Cuts and “Deserted” Towns

Merger Showdown: Union Slams Crédit Agricole–Banco BPM Deal Over Job Cuts and “Deserted” Towns

Union Sounds Alarm on Bank Merger Italian bank workers’ union First CISL has delivered a stark warning about the rumored merger between Banco BPM and Crédit Agricole Italia. On October 31, the union publicly rejected the potential deal, saying it would come at a high social cost. “An eventual Crédit Agricole–Banco BPM operation will bring a new wave of branch closures [and] heavy cuts to jobs,” cautioned First CISL Secretary General Riccardo Colombanifirstcisl.it. He stressed that hundreds of bank branches could shut if the two lenders combine, hurting not only bank employees but also local communities and small businesses that
3 November 2025
Brighthouse Financial (BHF) Stock Soars on Takeover Buzz – Price Jump, Earnings Outlook & Expert Analysis

Brighthouse Financial (BHF) Stock Soars on Takeover Buzz – Price Jump, Earnings Outlook & Expert Analysis

Short-Term and Long-Term Outlook Deal or No Deal: In the short term, Brighthouse’s fate may hinge on the takeover negotiations. If Aquarian finalizes a buyout near $70/share, the stock could quickly gravitate toward that price (roughly 25% above where it traded post-rumor) and shareholders would lock in a substantial one-time gaininvesting.com. Market watchers note that private equity interest in life insurers is driven by the opportunity to earn higher returns on insurers’ investment portfoliosreuters.com. Aquarian’s rumored ~$4 billion offer (at $70) underscores that strategic buyers see more value in Brighthouse than the public market does – a sentiment echoed by
31 October 2025
··
Chevron (CVX) Stock Rallies on $2B Pipeline Deal – Could $200 Be Next?

Chevron’s Next Big Move: CVX Stock Could Skyrocket on $55B Hess Deal & Low-Carbon Push

In summary, as of Oct 31, 2025 Chevron stands as a dividend-rich, integrated energy leader navigating a weak-oil cycle. Its stock is trading near multi-month lows but backed by record production and cash flow. Short-term catalysts include the Hess synergies and any rebound in oil prices. Longer-term, Chevron emphasizes high-return oil projects (Guyana, Permian) and steady shareholder returns, while gradually investing in lower-carbon ventures. Key factors to watch are global oil demand trends (especially in Asia), OPEC supply decisions, and the results of Q4 earnings (including Exxon, Shell). Analyst consensus sees moderate upside if oil stabilizes, but Chevron – “one of
31 October 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Bidding War Ignites for Obesity Biotech Novo’s takeover push marks a sudden escalation in the weight-loss drug wars. The Danish company – maker of Wegovy and Ozempic – broke ranks on Oct. 30 by notifying Metsera’s board of its superior bidreuters.com. This move comes just days after the foundation coup at Novo (demanding faster U.S. growth)reuters.com, signaling a full-aggression strategy. Metsera confirmed the offer is “superior” to Pfizer’s, giving Pfizer four business days to respondts2.tech. Pfizer CEO Albert Bourla has publicly talked up this obesity play, so Pfizer is not likely to concede easily. Unsurprisingly, Pfizer immediately denounced Novo’s counterbid
31 October 2025
·
Activist Investor Shocks Wall Street: $10.9B Comerica Sale Sparks Bank M&A Boom

Activist Investor Shocks Wall Street: $10.9B Comerica Sale Sparks Bank M&A Boom

Activist Investors Target Underperforming Banks Until recently, regional banks drew little activist attention. That changed when HoldCo Asset Management loudly challenged Comerica’s board. In July 2025 HoldCo issued a report warning that Comerica and other midsize banks had underperformed due to poor management decisionsts2.techts2.tech. Within weeks, Comerica’s management began formally exploring strategic options, leading to the Fifth Third deal. HoldCo’s founders Vik Ghei and Misha Zaitzeff explained that many regional bank CEOs were overpaid and under-delivering – and they vowed to “shame” boards into action (via proxy fights if necessary)intellectia.aits2.tech. After Comerica, HoldCo moved on: it recently threatened a proxy
31 October 2025
·
Rocket Companies Stock Blasts Off After $14B Mega-Merger – Will RKT Keep Soaring?

Rocket Companies (RKT) Stock Soars after $14B Mortgage Mega-Merger and Earnings Beat – What’s Next?

Stock Performance and Recent Moves Rocket Companies (NYSE: RKT) has been one of 2025’s surprise gainers in the mortgage sector. Its shares peaked in the low-$20s in early October on merger excitement, but have since pulled back into the mid-$16sts2.techstockanalysis.com. On Oct. 29 the stock slid about 7% (closing $16.24) before jumping ~5% in after-hours trading on Oct. 30 after the earnings beatstockanalysis.cominvesting.com. Even after the recent dip, RKT trades far above last year’s ~$10 lowts2.tech. For context, its 52-week range is roughly $10.06–$22.55reuters.com. Investors have noted the stock’s volatility – Reuters data show its beta is ~2.2 – meaning
30 October 2025
·
Terex (TEX) Stock Crashes 18% on Surprise REV Group Merger News

Terex (TEX) Stock Crashes 18% on Surprise REV Group Merger News

In-Depth Analysis Terex’s stock slump on Oct. 30 came amid two shocks: mixed Q3 earnings results and a transformational merger announcement. After a previous close near $56, shares briefly traded in the mid-$40s, reflecting roughly an 18% intraday fallstockanalysis.comts2.tech. Ts2.tech noted that “Terex fell ~18%” after the quarter (“weaker revenue”) newsts2.tech, a move echoed by institutional traders and option activity. By afternoon, volume had spiked and the stock was well below pre-earnings levels. For context, the 52-week range is $31.53–$58.66stockanalysis.com, so even after the drop, shares remain above their 2025 low (around $32 last winter) but well off recent highs.
30 October 2025
···
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Bidding War Sends Metsera Shares Higher Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash (about $4.9B) plus up to $22.50 in contingent paymentssec.gov. Pfizer CEO Albert Bourla said this deal “propels Pfizer into this key therapeutic area” of obesity treatmentsec.gov. Metsera CEO Whit Bernard called the deal “an excellent outcome for our shareholders” and praised the chance to “realize the promise of improved human health at scale” under Pfizer’s wingsec.gov. On Oct. 30, Novo Nordisk dramatically entered the fray with an unsolicited offer
30 October 2025
·
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo’s counter-offer details Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolioreuters.com. According to MarketScreener (Dow Jones Newswires), the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRsmarketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront (about $28.50/share) plus CVRs, for up to ~$7.3Bts2.techreuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts. Novo’s CEO Maziar “Mike” Doustdar hailed the move as proof of the company’s ambition. In
30 October 2025
··
Alaska-Hawaiian Merger Takes Off: Single Operating Certificate and More

Alaska-Hawaiian Merger Takes Off: Single Operating Certificate and More

What This Means for Travelers Behind the scenes, Alaska’s takeoff toward full integration will be mostly transparent to customers. Travel itineraries and loyalty points carry over automatically, and the Hawaiian brand on island‑only routes remains in place airlinegeeks.com. Flight numbers and booking codes have already switched: passengers who booked on HA numbers need do nothing – their flights are now AS flights beatofhawaii.com. Free Wi‑Fi via Starlink (when installed) and an expanded network will be the tangible benefits in the cabin. As Alaska’s CEO put it, the goal is “one combined airline” in terms of systems, safety and service, without
29 October 2025
·
Pepsi Bottler Goes Boozy: Varun Beverages Surges on Carlsberg Beer Deal & Q3 Profit Jump

Pepsi Bottler Goes Boozy: Varun Beverages Surges on Carlsberg Beer Deal & Q3 Profit Jump

Varun Beverages’ Big Pivot: From Colas to Carlsberg After decades of selling PepsiCo sodas and bottled water, Varun Beverages is making a bold pivot into booze. The company’s board on Wednesday approved adding alcoholic drinks to its business scope, a strategic move to diversify beyond soft drinks. “In response to the growing popularity of Ready To Drink (RTD) and [a] variety of alcoholic beverages, VBL sees an opportunity for expansion into [this] business… including beer, wine, liquor, brandy, whisky, gin, rum, [and] vodka in India & abroad,” the company said in a statementndtvprofit.com. In other words, the Pepsi bottler will now also
29 October 2025
·
Cygnet’s $1.4 B Oil Patch Power Play – Kiwetinohk Shareholders Score Big Premium in Alberta Energy Deal

Cygnet’s $1.4 B Oil Patch Power Play – Kiwetinohk Shareholders Score Big Premium in Alberta Energy Deal

Deal Overview & Terms In a significant shake-up for the Canadian oil and gas sector, Cygnet Energy – a privately held exploration and production company – has agreed to buy publicly traded Kiwetinohk Energy Corp. in an all-cash acquisition. Announced on October 28, 2025, the definitive arrangement agreement will see Cygnet pay C$24.75 per share for all Kiwetinohk common sharesreuters.comreuters.com. This values the transaction at approximately C$1.4 billion (including debt), just shy of US$1 billion. The takeover will be executed via a court-approved Plan of Arrangement under Canadian law and is expected to close by late December 2025, assuming regulatory and shareholder
28 October 2025
··
Huntington Bancshares’ Bold Moves: Strong Earnings and a $7.4B Bank Takeover Shake Up HBAN Stock

Huntington Bancshares’ Bold Moves: Strong Earnings and a $7.4B Bank Takeover Shake Up HBAN Stock

October 27, 2025: Huntington Bancshares Incorporated (NASDAQ: HBAN) is making headlines with a potent mix of robust earnings and aggressive expansion. The Columbus, Ohio-based regional bank is riding high on better-than-expected Q3 results and announcing a $7.4 billion takeover of Cadence Bank, a bold merger that extends Huntington’s footprint into the lucrative Texas and Southeast markets. Investors are parsing what these developments mean for HBAN’s stock price and future. Stock Price and Recent Trading Action As of October 27, Huntington’s stock is hovering near $15.5 per share in afternoon trading. That price is down a few percent from Friday’s close,
27 October 2025
·
American Water & Essential Utilities to Merge in $63B ‘Mega-Deal’ – What Investors Need to Know

American Water & Essential Utilities to Merge in $63B ‘Mega-Deal’ – What Investors Need to Know

In-Depth Report: On Oct. 26, 2025, American Water Works Co. (AWK) and Essential Utilities, Inc. (WTRG) surprised the utilities sector by announcing a definitive all-stock merger agreement Businesswire Investing. The companies said the combination creates the largest regulated water/wastewater utility in the U.S., serving roughly 14 million people in 14 states ts2.tech. According to the companies, shareholders of each firm unanimously approved the deal, which carries a pro forma market value of about $40 billion (about $63 billion including debt) Marketscreener Nasdaq. American Water shareholders will receive 0.305 shares for each Essential share, equating to a ~10% premium to WTRG’s recent trading
27 October 2025
·
Huntington’s $7.4B Texas-Tupelo Power Move: Cadence Bank Takeover Shakes Up Banking

Huntington’s $7.4B Texas-Tupelo Power Move: Cadence Bank Takeover Shakes Up Banking

Deal Details and Rationale On Oct. 27, Huntington Bancshares announced it will absorb Cadence Bank in a stock-for-stock merger finimize.com sec.gov. Cadence is a $53 billion-asset regional bank based in Houston/Tupelo, with 390 branches in eight states sec.gov bankingdive.com. Under the deal Huntington will issue 2.475 of its shares per Cadence share. Based on HBAN’s Oct. 24 close of $16.07, the exchange price equals $39.77 per Cadence share (a ~9% premium) finimize.com bankingdive.com. This values Cadence at $7.4 billion in total finimize.com bankingdive.com. The combined bank will have about $276 billion in assets, $220 billion in deposits, and $184 billion in loans and leases reuters.com bankingdive.com.
27 October 2025
RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

RNA Stock Skyrockets: Avidity Biosciences Soars on $12B Novartis Buyout and Breakthrough Trials

Stock Performance & Recent Trends Prior to the buyout news, RNA stock had been on a steady uptrend in 2025. The share price more than doubled from the low-$20s a year ago to the high-$40s this month ts2.tech. In the past three months alone, RNA jumped ~40%, fueled by upbeat clinical updates and M&A speculation ts2.tech. The stock hit a 52-week peak of $56 in early October ts2.tech after its lead DMD therapy showed strong results and secured FDA Breakthrough designation. Shares pulled back slightly to around $49 by late October, but remained up 100%+ year-over-year ts2.tech. A major catalyst
27 October 2025
·····
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the massive value of RNA therapeutics for rare diseases – and signals that big pharma’s biotech spending spree isn’t slowing down. While Avidity’s chapter as an independent company is closing, its novel treatments may reach patients faster under Novartis’s umbrella. Investors now await the finalization of the deal (and SpinCo details), as Wall Street cheers another biotech success story in the making. 🏥💥 Sources: reuters.comreuters.combusiness-standard.combiospace.combiospace.commarketbeat.comts2.techmarketbeat.comsahmcapital.comsahmcapital.combiospace.combiospace.combusiness-standard.comreuters.combusiness-standard.comreuters.comreuters.comts2.techts2.techbiospace.combiospace.combiospace.combiospace.com
26 October 2025
··
DraftKings Bets Big: Railbird Acquisition and NBC Deal Ignite Investor Frenzy

DraftKings Bets Big: Railbird Acquisition and NBC Deal Ignite Investor Frenzy

Record Revenue, Rising Margins Drive Optimism In early August, DraftKings reported blowout Q2 results – revenue of $1.51 billion (up 37% YoY) and adjusted EBITDA of $301 million, more than double the prior recordinvesting.com. Management noted strong sportsbook hold and growth in monthly active users. CEO Jason Robins said, “We set records for revenue, net income and Adjusted EBITDA in the second quarter”investing.com. The company reaffirmed its full-year outlook, expecting to hit the high end of $6.2–6.4B revenue and roughly $850M EBITDAinvesting.com. The upbeat results lifted DraftKings shares (they rose ~4% immediately after releaseinvesting.com) and helped narrow the gap with archrival FanDuel
25 October 2025
·
1 … 15 16 17 18 19 20

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop